Production of Y-86 and other radiometals for research purposes using a solution target system

Oehlke, Elisabeth; Hoehr, Cornelia; Hou, Xinchi; Hanemaayer, V.; Zeisler, Stefan; Adam, Michael J.; Ruth, Thomas J.; Celler, Anna; Buckley, K.; Bénard, François; Schaffer, Paul

doi:10.1016/j.nucmedbio.2015.06.005

Cited by 46 publications

(44 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since those cyclotrons have in general only liquid and gaseous targets (to produce 18 F, 11 C, 15 O, etc. ), two conspicuous developments have come up, namely to install solid targetry [38] or to utilize an existing or modified liquid target for irradiating solutions of target isotopes [39,40]. In the latter case, effort is needed to separate radiation-induced chemical species.…”

Section: Production Methodologiesmentioning

confidence: 99%

See 1 more Smart Citation

The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y

2017

View full text Add to dashboard Cite

In the context of radiopharmacy and molecular imaging, the concept of theranostics entails a therapy-accompanying diagnosis with the aim of a patient-specific treatment. Using the adequate diagnostic radiopharmaceutical, the disease and the state of the disease are verified for an individual patient. The other way around, it verifies that the radiopharmaceutical in hand represents a target-specific and selective molecule: the “best one” for that individual patient. Transforming diagnostic imaging into quantitative dosimetric information, the optimum radioactivity (expressed in maximum radiation dose to the target tissue and tolerable dose to healthy organs) of the adequate radiotherapeutical is applied to that individual patient. This theranostic approach in nuclear medicine is traced back to the first use of the radionuclide pair 86Y/90Y, which allowed a combination of PET and internal radiotherapy. Whereas the β-emitting therapeutic radionuclide 90Y (t½ = 2.7 d) had been available for a long time via the 90Sr/90Y generator system, the β+ emitter 86Y (t½ = 14.7 h) had to be developed for medical application. A brief outline of the various aspects of radiochemical and nuclear development work (nuclear data, cyclotron irradiation, chemical processing, quality control, etc.) is given. In parallel, the paper discusses the methodology introduced to quantify molecular imaging of 86Y-labelled compounds in terms of multiple and long-term PET recordings. It highlights the ultimate goal of radiotheranostics, namely to extract the radiation dose of the analogue 90Y-labelled compound in terms of mGy or mSv per MBq 90Y injected. Finally, the current and possible future development of theranostic approaches based on different PET and therapy nuclides is discussed.

show abstract

Section: Production Methodologiesmentioning

confidence: 99%

“…In the latter case, effort is needed to separate radiation-induced chemical species. The yield of 86 Y achieved using a liquid target is generally low, but it may be enough for local use [40]. …”

Section: Production Methodologiesmentioning

confidence: 99%

The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y

2017

View full text Add to dashboard Cite

show abstract

“…In recent years, a new impulse has come to the production of 86 Y via the 86 Sr(p,n) reaction at hospital‐based cyclotrons. An existing or modified liquid target has been utilized for irradiating a solution of the target isotope . However, this involves an effort to separate radiation‐induced chemical species.…”

Section: Novel Positron Emission Tomography Radionuclidesmentioning

confidence: 99%

“…A detailed discussion on the use of different chargedparticle-induced reactions over several energy ranges for the production of novel positron emitters is given in several references. 6,17,18 We consider below 4 radionuclides, namely, 64 Cu, 86 Y, 124 I, and 73 Se. They were mainly developed in our Institute, and the methodologies described here should serve as typical examples of the techniques and technologies involved in the utilization of chargedparticle beams of various energies.…”

Section: Novel Positron Emission Tomography Radionuclidesmentioning

confidence: 99%

See 1 more Smart Citation

Development of novel radionuclides for medical applications

Qaim

Spahn

2017

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Medical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to nonstandard positron emitters (eg, Cu, Y, I, and Se) and novel therapeutic radionuclides emitting low-range β particles (eg, Cu and Re), conversion or Auger electrons (eg, Sn and Br), and α particles (eg, Ac). A brief account of various aspects of development work (ie, nuclear data, targetry, chemical processing, and quality control) is given. For each radionuclide under consideration, the status of technology for clinical scale production is discussed. The increasing need of intermediate-energy multiple-particle accelerating cyclotrons is pointed out.

show abstract